ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business, and a wholly-owned subsidiary of Harrow Health, Inc. (NASDAQ: HROW), announced that it has agreed to a product supply agreement with EyeCare Services Partners (ESP). ImprimisRx currently provides a limited number of ophthalmic formulations to practices within the ESP group, but this agreement will expand the number of formulations available to new and existing ESP facilities and allow for additional formulations to be added as the ImprimisRx/ESP relationship continues to expand. ESP is a partnership of 30+ ophthalmologic, optometric brands, and ambulatory surgery centers (ASCs) across multiple states, with 90 locations, 12 ASCs, and 200 providers, representing approximately 100,000 ophthalmic procedures in the U.S. annually.
John Saharek, President of ImprimisRx, commented, “EyeCare Services Partners has built an impressive network of eye care providers nationwide and we are honored they have entrusted us with the health outcomes of their patients. ESP is focused on minimizing distractions and disruptions to patient care and greater access to the ImprimisRx portfolio will support that goal, especially as we continue to innovate and build new solutions in different corners of the ophthalmology market.”
Kyle McKinnon, Product Manager – Refractive Marketing of EyeCare Services Partners, stated, “I am looking forward to expanding our relationship with ImprimisRx and bringing more of their products into our network. ImprimisRx has been a reliable provider of many critical formulations for some time now but, with their ever-expanding portfolio, I see additional opportunities to supply unique, customizable solutions to our healthcare providers and patients.”
Source: Biospace
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.